Sionna Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Sionna Therapeutics details increased operating expenses and ongoing clinical trial progress in its Q2 2026 Form 10-Q filing.
NASDAQ
Sionna Therapeutics reported a net loss of $26.8 million for Q1 2026, with increased operating expenses primarily in R&D and G&A, while maintaining a cash runway projected into 2028.
NASDAQ
Sionna Therapeutics reported a net loss of $20.3 million for Q3 2025, advancing its lead cystic fibrosis drug candidates SION-719 and SION-451 into later-stage clinical trials.
NASDAQ
Sionna Therapeutics announced positive topline Phase 1 data for its lead NBD1 stabilizer candidates, SION-719 and SION-451, while reporting increased operating losses for Q2 2025.
NASDAQ
Sionna Therapeutics reports a net loss of $16.5 million for Q1 2025, highlighting ongoing investments in research and development for its cystic fibrosis therapies.